{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:48:25Z","timestamp":1793825305499,"version":"4.6.1"},"reference-count":25,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Risk &amp; Safety in Medicine"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:p>In this commentary we review the recent approval of escitalopram for generalized anxiety disorder (GAD) in children and adolescents. We critically discuss the FDA approval document and the approval trial. In the approval trial, efficacy was not clinically meaningful, statistical significance uncertain, and there were significantly more adverse events with escitalopram than with placebo. Relative to placebo, children and adolescents exposed to escitalopram were more likely to become suicidal than to experience a clinically relevant improvement in anxiety. Overall, the harm-benefit ratio seems problematic for escitalopram for pediatric GAD.<\/jats:p>","DOI":"10.1177\/09246479261456063","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T13:47:28Z","timestamp":1779976048000},"page":"577-581","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Concerning the harm-benefit ratio of escitalopram for pediatric generalized anxiety disorder. A critical viewpoint on the evidence and approval process"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4659-9314","authenticated-orcid":false,"given":"Martin","family":"Pl\u00f6derl","sequence":"first","affiliation":[{"name":"Paracelsus Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1318-2029","authenticated-orcid":false,"given":"Mark","family":"Horowitz","sequence":"additional","affiliation":[{"name":"North East London NHS Foundation Trust"},{"name":"King\u2019s College London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3760-3801","authenticated-orcid":false,"given":"Florian","family":"Naudet","sequence":"additional","affiliation":[{"name":"University of Rennes, Rennes University Hospital, Inserm, Rennes Clinical Investigation Center (CIC1414), Clinical Pharmacology Department, Institute for Research in Health, Environment and Work (Irset)-UMR_S 1085, Rennes, France"},{"name":"Institut Universitaire de France (IUF)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Warren","sequence":"additional","affiliation":[{"name":"Ipswich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1214-6974","authenticated-orcid":false,"given":"Joanna","family":"Moncrieff","sequence":"additional","affiliation":[{"name":"University College London"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"e_1_3_5_2_2","first-page":"381","volume-title":"Mental health treatment among children aged 5\u201317 years: united States, 2019","author":"Zablotsky B","year":"2020","unstructured":"Zablotsky B, Terlizzi EP. Mental health treatment among children aged 5\u201317 years: united States, 2019. NCHS Data Brief, 2020, p. 381. https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db381.htm"},{"key":"e_1_3_5_3_2","volume-title":"New pediatric labeling information database (Duloxetine)","author":"Food and Drug Administration","year":"2015","unstructured":"Food and Drug Administration. New pediatric labeling information database (Duloxetine), 2015. https:\/\/www.accessdata.fda.gov\/scripts\/sda\/sdDetailNavigation.cfm?id=150939E31ED20ED2E053564DA8C00176&rownum=310&sd=labelingdatabase&utm_source=chatgpt.com"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-064245"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2023.0004"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2023.0029"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2023.0089"},{"key":"e_1_3_5_8_2","unstructured":"Food and Drug Administration. Multi-disciplinary review and evaluation LEXAPRO (escitalopram) tablets\/oral solution 2023. https:\/\/www.fda.gov\/media\/170239\/download?attachment"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.janxdis.2025.103070"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X05276863"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2020-111600"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2025.05.010"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-015-0153-1"},{"issue":"5","key":"e_1_3_5_14_2","first-page":"CD013674","article-title":"New generation antidepressants for depression in children and adolescents: a network meta-analysis","volume":"5","author":"Hetrick SE","year":"2021","unstructured":"Hetrick SE, McKenzie JE, Bailey AP, et al. New generation antidepressants for depression in children and adolescents: a network meta-analysis. Cochrane Database Syst Rev 2021; 5(5): CD013674. https:\/\/doi.org\/10.1002\/14651858.CD013674.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31793-8"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20m13396"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2880"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181a5233f"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2025.116497"},{"key":"e_1_3_5_20_2","first-page":"924647925133788","article-title":"Restoring TADS: RIAT reanalysis of the treatment for adolescents with depression study","volume":"36","author":"Aboustate N","year":"2025","unstructured":"Aboustate N, Jureidini J, Woodman R, et al. Restoring TADS: RIAT reanalysis of the treatment for adolescents with depression study. Int J Risk Saf Med 2025; 36: 9246479251337880. https:\/\/doi.org\/10.1177\/09246479251337879","journal-title":"Int J Risk Saf Med"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4320"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.3233\/JRS-210034"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00018"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000002054"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2025.112016"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmae063"}],"container-title":["International Journal of Risk &amp; Safety in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09246479261456063","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09246479261456063","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09246479261456063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:37:54Z","timestamp":1793785074000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09246479261456063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1177\/09246479261456063"],"URL":"https:\/\/doi.org\/10.1177\/09246479261456063","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/09246479261456063\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479261456063\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479261456063\/v3\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479261456063\/v3\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479261456063\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479261456063\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479261456063\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479261456063\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479261456063\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479261456063\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/09246479261456063\/v2\/decision1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.31234\/osf.io\/6fqk4_v3","asserted-by":"object"}]},"ISSN":["0924-6479","1878-6847"],"issn-type":[{"value":"0924-6479","type":"print"},{"value":"1878-6847","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}